Cancer Discov. 2022 May 2;12(5):1176. doi: 10.1158/2159-8290.CD-NB2022-0019.
The FDA has approved ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy targeting BCMA, as a fifth-line option for patients with relapsed/refractory multiple myeloma. Cilta-cel is the second agent in its class to get a regulatory thumbs-up in less than a year.
美国食品和药物管理局 (FDA) 已批准 cilta-cel（嵌合抗原受体 T 细胞疗法，针对 BCMA）作为复发性/难治性多发性骨髓瘤患者的五线治疗选择。不到一年时间，cilta-cel 是该类别中第二个获得监管机构批准的药物。
